Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Apatinib in RAIR-DTC
NCT04560127Phase 2Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2020
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in differentiated thyroid cancer (DTC), sponsored by Peking Union Medical College Hospital. Started Sep 2020; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT04560127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560127.